Chiesi breaks ground on new R&D headquarters in Palma
pharmafile | July 13, 2009 | News story | Research and Development |Â Â Chiesi, Europe, ItalyÂ
Construction of Chiesi's new 70 million euro centre for research and development has begun in Parma, Italy.
The Italian company says the centre will open in 2011, and will employ an international team of over 300 scientists to discover promising new treatments for respiratory diseases.
The centre will become the hub of the group's global R&D network, and contribute to its long-term aims of international expansion.
Paolo Chiesi, vice chairman and research and development director for the company, said: "The new research centre reaffirms the role that Parma plays as our headquarters for the Chiesi group, and will enable us to intensify our internal research and development activities by integrating them with those at our other R&D sites in France, the United Kingdom and the US.
"The centre will also enhance the process of bringing together a vital group of skills, thus facilitating our existing partnerships with the academic world and other research centres, to create the basis for new projects and take advantage of synergy opportunities between the public and private sectors".
In 2008, Chiesi invested 108 million euros in R&D accounting for 14.5% of the company's turnover, standing at 749 million euros, 62% of which was generated in international markets.
"This investment represents confirmation of strategies that are evidence of our strong commitment to the research and development of new drugs", says Alberto Chiesi, chairman and managing director of the group.
"The Chiesi Group is currently tackling a particularly significant phase in its growth. Its direct presence in key European markets, its recent debut in the US and this new research centre further consolidate our international role in the respiratory disease sector, as well as that of special care."
Chiesi has also recently made a move to boost its presence in the all-important US market with the acquisiton of Cornerstone Therapeutics. The company now holds a majority stake in the company, and will shortly take over the US marketing of Cornerstone's Curosurf, a leading treatment for respiratory distress syndrome in premature babies.
Chiesi already has a clinical research unit in Rockville (Maryland) and this will continue to operate as an independent unit.
Related Content
Chiesi expands La Chaussée-Saint-Victor site to manufacture next-gen inhalers
Chiesi, a biopharma group focused on treating respiratory diseases, has inaugurated an expansion of its …
NICE recommends treatment for rare genetic eye disorder
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending …
Great Place To Work® and Fortune Name Chiesi Group No. 23in 2024 World’s Best Workplaces™ List
Chiesi is the only European pharmaceutical company and the first Italian company ever to be …
